Who
Jane L. Mendillo
Director
Company insider
Files Form 4 as: Director, Generate Biomedicines; Director, Lazard; Director, General Motors.
In numbers
- Trades disclosed
- 66
- Buys
- 5
- Sells
- 0
- Bought
- $247K
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 20 Apr 2016
- Last trade
- 2 Mar 2026
- Last filed
- 2 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Mar 2026filed 2 Mar 2026 | GENB Generate BiomedicinesBiotechnology | SEC FORM 4 Bought | $24K1,500 at $16.00 | filing |
| 2 Mar 2026filed 2 Mar 2026 | GENB Generate BiomedicinesBiotechnology | SEC FORM 4 Bought | $24K1,500 at $16.00 | filing |
| 26 Feb 2026filed 2 Mar 2026 | GENB Generate Biomedicinesoption or derivative · Biotechnology | SEC FORM 4 Code A | —29,561 at $0.00 | filing |
| 26 Feb 2026filed 2 Mar 2026 | GENB Generate Biomedicinesoption or derivative · Biotechnology | SEC FORM 4 Code A | —29,561 at $0.00 | filing |
| 18 Feb 2025filed 20 Feb 2025 | LAZ Lazardoption or derivative · Capital Markets & Asset Management | SEC FORM 4 Code A | —642 at $0.00 | filing |
| 15 Nov 2024filed 19 Nov 2024 | LAZ Lazardoption or derivative · Capital Markets & Asset Management | SEC FORM 4 Code A | —636 at $0.00 | filing |
| 15 Aug 2024filed 19 Aug 2024 | LAZ Lazardoption or derivative · Capital Markets & Asset Management | SEC FORM 4 Code A | —766 at $0.00 | filing |
| 3 Jun 2024filed 5 Jun 2024 | LAZ Lazardoption or derivative · Capital Markets & Asset Management | SEC FORM 4 Code A | —4,307 at $0.00 | filing |
| 15 May 2024filed 15 May 2024 | LAZ Lazardoption or derivative · Capital Markets & Asset Management | SEC FORM 4 Code A | —899 at $0.00 | filing |
| 15 Feb 2024filed 16 Feb 2024 | LAZ Lazardoption or derivative · Capital Markets & Asset Management | SEC FORM 4 Code A | —953 at $0.00 | filing |
| 15 Nov 2023filed 17 Nov 2023 | LAZ Lazardoption or derivative · Capital Markets & Asset Management | SEC FORM 4 Code A | —1,284 at $0.00 | filing |
| 15 Aug 2023filed 17 Aug 2023 | LAZ Lazardoption or derivative · Capital Markets & Asset Management | SEC FORM 4 Code A | —1,031 at $0.00 | filing |
| 1 Jun 2023filed 5 Jun 2023 | LAZ Lazardoption or derivative · Capital Markets & Asset Management | SEC FORM 4 Code A | —6,039 at $0.00 | filing |
| 15 May 2023filed 17 May 2023 | LAZ Lazardoption or derivative · Capital Markets & Asset Management | SEC FORM 4 Code A | —1,237 at $0.00 | filing |
| 15 Feb 2023filed 17 Feb 2023 | LAZ Lazardoption or derivative · Capital Markets & Asset Management | SEC FORM 4 Code A | —937 at $0.00 | filing |
| 15 Nov 2022filed 17 Nov 2022 | LAZ Lazardoption or derivative · Capital Markets & Asset Management | SEC FORM 4 Code A | —914 at $0.00 | filing |
| 15 Aug 2022filed 17 Aug 2022 | LAZ Lazardoption or derivative · Capital Markets & Asset Management | SEC FORM 4 Code A | —894 at $0.00 | filing |
| 1 Jun 2022filed 3 Jun 2022 | LAZ Lazardoption or derivative · Capital Markets & Asset Management | SEC FORM 4 Code A | —4,914 at $0.00 | filing |
| 16 May 2022filed 18 May 2022 | LAZ Lazardoption or derivative · Capital Markets & Asset Management | SEC FORM 4 Code A | —1,102 at $0.00 | filing |
| 15 Feb 2022filed 17 Feb 2022 | LAZ Lazardoption or derivative · Capital Markets & Asset Management | SEC FORM 4 Code A | —934 at $0.00 | filing |
News
Zealand And Generate Biomedicines Team Up To Develop AI-Designed Therapies For Metabolic DiseasesGENB · rttnews.com · 14 Oct 2026Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic DiseasesGENB · manilatimes.net · 13 Oct 2026Contrasting Oramed Pharmaceuticals (NASDAQ:ORMP) & Generate Biomedicines (NASDAQ:GENB)GENB · tickerreport.com · 11 Oct 2026
0 headlines in the last 90 days name Jane L. Mendillo; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.